Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BE3-gMH is an experimental in vivo **CRISPR cytosine base-editing** intervention comprising base editor 3 and the gMH guide RNA. Delivered to mouse liver using an adenoviral vector, it directs C-to-T base conversion at the PCSK9 locus near codon W159, generating predominantly nonsense loss-of-function alleles in human PCSK9 and mouse Pcsk9 without creating intended DNA double-strand breaks. In a human-PCSK9 knock-in hypercholesterolemic mouse model, it reduced circulating PCSK9 and total cholesterol; it remains a preclinical research construct with no assigned INN or marketed product. ([link.springer.com](https://link.springer.com/content/pdf/10.1186/s12915-018-0624-2.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BE3-gMH.